18F-Fluciclovine PET and Multiparametric MR Imaging
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the use of the investigational agent Axumin
(fluciclovine-F18) with PET/CT imaging in combination with standard MR imaging to detect
remaining or recurrent brain tumor.